Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Concord DrugsBOM:538965 +0.66%67 Return-on-Tangible-Equity is 4.35% as of Mar. 2026, which is 140% above its 10-year median of 1.81. GuruFocus rates BOM:538965 with a GF Score™ of 67/100 and a GF Value™ of ₹60.96 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 899 Drug Manufacturers companies, Concord Drugs ranks worse than 64.4% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Concord Drugs's annualized net income for the quarter that ended in Mar. 2026 was ₹21.1 Mil. Concord Drugs's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹485.1 Mil. Therefore, Concord Drugs's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 4.35%.
The historical rank and industry rank for Concord Drugs's Return-on-Tangible-Equity or its related term are showing as below:
BOM:538965'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0.94 Med: 1.81 Max: 13.06
Current: 2.7
During the past 13 years, Concord Drugs's highest Return-on-Tangible-Equity was 13.06%. The lowest was 0.94%. And the median was 1.81%.
BOM:538965's Return-on-Tangible-Equity is ranked worse than 64.4% of 899
companies
in the Drug Manufacturers industry
Industry Median: 7.87
vs BOM:538965: 2.70
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Concord Drugs Return-on-Tangible-Equity Related Terms
Concord Drugs Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Concord Drugs's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:538965 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Concord Drugs's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Drugs Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Concord Drugs's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Concord Drugs's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 4.35% mean?
Concord Drugs (BOM:538965) has a Return-on-Tangible-Equity of 4.35% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Concord Drugs and its competitors. This is 140% above median its historical median of 1.81. Over the past decade, Concord Drugs' Return-on-Tangible-Equity has ranged from 0.94 to 13.06. According to the industry distribution chart, Concord Drugs ranks #579 out of 899 companies in the Drug Manufacturers industry, placing it in the top 64.4%.
Is Concord Drugs' Return-on-Tangible-Equity too high?
Concord Drugs' current Return-on-Tangible-Equity of 4.35% is 140% above median its 10-year median of 1.81. Over the past 10 years, this metric has ranged from a low of 0.94 to a high of 13.06. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.87. Concord Drugs' value of 4.35% is 44.7% below this industry median. Based on the distribution chart, Concord Drugs ranks #579 out of 899 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Concord Drugs has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Concord Drugs' Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Concord Drugs ranks #579 out of 899 companies for Return-on-Tangible-Equity. This places Concord Drugs in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.87. Concord Drugs' value of 4.35% is 44.7% below this benchmark. Historically, Concord Drugs' own Return-on-Tangible-Equity has ranged from 0.94 to 13.06 over the past decade. While the company's 10-year median is 1.81 vs. the industry median of 7.87, Concord Drugs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.87, based on 899 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Concord Drugs's current Return-on-Tangible-Equity of 4.35% is 44.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Concord Drugs and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Drugs's current Return-on-Tangible-Equity is 4.35%, which is 140% above median its own 10-year median of 1.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Drugs stock overvalued right now?
Based on GuruFocus' analysis, Concord Drugs (BOM:538965) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹60.96, compared to a current price of ₹71.70 — trading 17.6% above its estimated fair value. The current Return-on-Tangible-Equity is 4.35%, which is 140% above median its 10-year median of 1.81 and 44.7% below the Drug Manufacturers industry median of 7.87. Concord Drugs' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Concord Drugs (BOM:538965), the current Return-on-Tangible-Equity is 4.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Drugs (BOM:538965) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Drugs stock appears to be overvalued.
The current stock price of ₹71.70 is trading 17.6% above its estimated GF Value™ of ₹60.96.
GuruFocus considers Concord Drugs to be Modestly Overvalued.
Key valuation signals for BOM:538965:
Return-on-Tangible-Equity: 4.35% (140% above median its 10-year median of 1.81)
GF Value™: ₹60.96 vs. price of ₹71.70 (17.6% above fair value)
Industry Position: 44.7% below the Drug Manufacturers median (#579 of 899)
No single metric tells the full story. See the BOM:538965 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers.
67GF Score
Get the complete analysis for BOM:538965
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:538965 has been successfully added to your 
